Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949098 | 0.72 | MAOA (0.56) | NQO2MAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19669636 | 0.71 | NQO2 (0.50) | NQO2MAOAMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27565961 | 0.71 | MAOA (0.55) | NQO2MAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2492094 | 0.69 | MAPT (0.57) | NQO2MAOAMEN1KMT2ASMN1; SMN2 | |
| Sulfuric Acid SCHEMBL6762068 | 0.69 | MAOA (0.52) | NQO2MAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10706980 | 0.69 | ALDH1A1 (0.50) | NQO2MAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10695073 | 0.67 | ALDH1A1 (0.55) | MAOAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL18682061 | 0.67 | CHRNB2 (0.57) | MEN1KMT2ASMN1; SMN2MAPTPOLB | |
| SCHEMBL2486089 | 0.66 | POLB (0.50) | NQO2MAOAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11610339 | 0.65 | PKM (0.47) | NQO2MAOAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-1756112-A1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Boehringer Ingelheim International GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005111040-A1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598353-A1 | Pyrrolobenzimidazolones and their use as antiproliferative agents | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | NQO2 330/4885MAOA 2842/4885MEN1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.